Icon (ICLR) – Research Analysts’ Recent Ratings Changes

Several analysts have recently updated their ratings and price targets for Icon (NASDAQ: ICLR):

• 7/31/2026 – Icon was given a new $194.00 price target by Robert W. Baird.
• 7/31/2026 – Icon had its price target raised by Citigroup Inc. from $165.00 to $180.00. They now have a “neutral” rating on the stock.
• 7/31/2026 – Icon had its “buy” rating reaffirmed by Truist Financial Corporation. They now have a $209.00 price target on the stock, up from $207.00.
• 7/30/2026 – Icon was upgraded by William Blair to “strong-buy”.
• 7/30/2026 – Icon was upgraded by Citigroup Inc. to “hold”.
• 7/28/2026 – Icon was upgraded by Zacks Research from “strong sell” to “hold”.
• 6/30/2026 – Icon was upgraded by Truist Financial Corporation from “hold” to “buy”. They now have a $207.00 price target on the stock, up from $159.00.
• 6/26/2026 – Icon had its price target raised by Mizuho from $180.00 to $190.00. They now have an “outperform” rating on the stock.
• 6/25/2026 – Icon had its price target raised by BMO Capital Markets from $160.00 to $187.00. They now have an “outperform” rating on the stock.
• 6/25/2026 – Icon had its price target raised by TD Cowen from $164.00 to $197.00. They now have a “buy” rating on the stock.
• 6/25/2026 – Icon had its price target raised by Citigroup Inc. from $140.00 to $165.00. They now have a “neutral” rating on the stock.
• 6/25/2026 – Icon was upgraded by Royal Bank Of Canada from “sector perform” to “outperform”. They now have a $185.00 price target on the stock, up from $126.00.
• 6/25/2026 – Icon had its price target raised by Barclays PLC from $160.00 to $175.00. They now have an “equal weight” rating on the stock.
• 6/25/2026 – Icon had its price target raised by JPMorgan Chase & Co. from $130.00 to $155.00. They now have a “neutral” rating on the stock.
• 6/25/2026 – Icon had its price target raised by Robert W. Baird from $168.00 to $186.00. They now have an “outperform” rating on the stock.
• 6/25/2026 – Icon had its price target raised by Bank of America Corporation from $125.00 to $150.00. They now have an “underperform” rating on the stock.
• 6/24/2026 – Icon was given a new $160.00 price target by UBS Group AG.
• 6/24/2026 – Icon had its price target raised by Barclays PLC from $150.00 to $160.00. They now have an “equal weight” rating on the stock.

Icon plc (NASDAQ: ICLR) is a global provider of outsourced drug development and clinical research services to the pharmaceutical, biotechnology and medical device industries. The company partners with clients at all stages of the product life cycle, offering expertise in protocol design, trial execution and regulatory compliance across a broad range of therapeutic areas.

Icon’s service portfolio encompasses clinical trial management, data management and biostatistics, medical imaging, pharmacovigilance and safety monitoring, laboratory sciences and specialized analytical solutions.